ARS Pharmaceuticals (SPRY) announced the launch of “Get neffy on Us,” a new integrated commercial program to help patients access their needle-free epinephrine medicine, neffy. Get neffy on Us was created to eliminate the time burden of an in-person office visit by offering a free visit with a virtual provider who can prescribe neffy. Eligible patients with commercial insurance may have a $0 co-pay for neffy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals resumed with a Buy at Roth Capital
- Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
- Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
- ARS Pharmaceuticals receives favorable decision from EPO on neffy
- ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating